Monday, June 22, 2026
Newsletter About
Business & Finance

AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion

Apogee Therapeutics is developing a promising atopic dermatitis drug.

This article was originally published by MarketWatch and is republished here under license.

Apogee Therapeutics is developing a promising atopic dermatitis drug.

More in Business & Finance

View All →

Leave a Reply

Discover more from The Meridian Review

Subscribe now to keep reading and get access to the full archive.

Continue reading